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ABSTRACT
Objective: The candidate malaria vaccine RTS,S/AS02A is a recombinant protein containing
part of the circumsporozoite protein (CSP) sequence of Plasmodium falciparum, linked to the
hepatitis B surface antigen and formulated in the proprietary adjuvant system AS02A. In a
recent trial conducted in children younger than age five in southern Mozambique, the vaccine
demonstrated significant and sustained efficacy against both infection and clinical disease. In a
follow-up study to the main trial, breakthrough infections identified in the trial were examined
to determine whether the distribution of csp sequences was affected by the vaccine and to
measure the multiplicity of infecting parasite genotypes.
Design: P. falciparum DNA from isolates collected during the trial was used for genotype
studies.
Setting: The main trial was carried out in the Manhic¸a district, Maputo province, Mozambique,
between April 2003 and May 2004.
Participants: Children from the two cohorts of the main trial provided parasite isolates as
follows: children from Cohort 1 who were admitted to hospital with clinical malaria; children
from Cohort 1 who were parasite-positive in a cross-sectional survey at study month 8.5;
children from Cohort 2 identified as parasite-positive during follow-up by active detection of
infection.
Outcome: Divergence of DNA sequence encoding the CSP T cell–epitope region sequence
from that of the vaccine sequence was measured in 521 isolates. The number of distinct P.
falciparum genotypes was also determined.
Results: We found no evidence that parasite genotypes from children in the RTS,S/AS02A arm
were more divergent than those receiving control vaccines. For Cohort 1 (survey at study
month 8.5) and Cohort 2, infections in the vaccine group contained significantly fewer
genotypes than those in the control group, (p ¼ 0.035, p ¼ 0.006), respectively, for the two
cohorts. This was not the case for children in Cohort 1 who were admitted to hospital (p ¼
0.478).
Conclusions: RTS,S/AS02A did not select for genotypes encoding divergent T cell epitopes in
the C-terminal region of CSP in this trial. In both cohorts, there was a modest reduction in the
mean number of parasite genotypes harboured by vaccinated children compared with
controls, but only among those with asymptomatic infections.
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INTRODUCTION
Malaria continues to be a major cause of morbidity and
mortality in many countries of Africa, and is estimated to
cause more than one million deaths each year [1]. Whereas
better use of available control measures and the search for
new, cheap, and effective drugs are the main aims of current
efforts in malaria research, sustainable control of malaria
would be enhanced if effective vaccines were available for use
in combination with other control measures.
Several malaria vaccine candidates have been tested in
malaria endemic countries [2], including the pre-erythrocyte
vaccine RTS,S/AS02A, a recombinant polypeptide developed
by GSK Biologicals that contains most of the C-terminal half
of the circumsporozoite protein (CSP) sequence of P.
falciparum fused to hepatitis B virus surface antigen formu-
lated in the AS02A adjuvant system [3,4]. Efﬁcacy against P.
falciparum infection in both experimentally infected volun-
teers and naturally exposed adults have been obtained with
this vaccine [3–5], and the protective efﬁcacy of RTS,S/AS02A
against clinical malaria was demonstrated recently in a proof-
of-concept Phase IIb, double-blind, randomised, controlled
trial in children aged 1–4 years in southern Mozambique [6].
Vaccine efﬁcacy for the ﬁrst or only episode was 29.9% (95%
CI 11.0–44.8; p ¼ 0.004) for clinical malaria and 57.7% (95%
CI 16.2–80.6; p¼ 0.019) for severe malaria over six months of
follow-up. The vaccine efﬁcacy for extending time to ﬁrst P.
falciparum infection was 45.0% (95% CI 31.4–55.9, p , 0.001).
Extended follow-up has conﬁrmed that protection is sus-
tained over 18 months post-vaccination [7].
CSP is an abundant protein found on the surface of the
sporozoite. The prevailing hypothesis in this ﬁeld is that cell-
mediated immune responses play an important role in
protection against pre-erythrocytic parasites, and studies of
the gene encoding CSP of P. falciparum have demonstrated a
signiﬁcant level of genetic polymorphism among isolates, the
most variable domains being the T cell epitopes near the C-
terminus of the protein, which are designated Th2R and
Th3R [8,9]. The inclusion of such variable sequences in the
vaccine may select for non vaccine-type alleles that could
impact on overall efﬁcacy, as non vaccine-type alleles were
selected by strain-speciﬁc vaccine responses to P. falciparum
merozoite protein MSP-2 among vaccinated Papua New
Guinean children [10]. In adult Gambian males, the RTS,S/
AS02A vaccine was found to induce protection against P.
falciparum infection that was not strain-speciﬁc [11]. The
parasite population in this study exhibited a high frequency
of alleles encoding T cell epitopes with the same amino-acid
sequence as those in the vaccine, which is based on laboratory
P. falciparum clone 3D7/NF54. Of the csp alleles identiﬁed by
dot-blotting, 10% encoded Th2R and 15% encoded Th3R
epitopes that were indistinguishable from those in the
vaccine. The prevalence of these alleles was similar among
emergent infections in the vaccine and the control groups
[11]. Interestingly, in the Gambian trial the number of
distinct parasite genotypes per infection (multiplicity of
infection (MOI)) in breakthrough cases was higher in the
RTS,S/AS02A group than in the control group (4.90 versus
4.23, p ¼ 0.05). These studies indicate that integrated
molecular typing will be a useful tool for the evaluation of
malaria vaccines, especially where a strain-speciﬁc effect is
possible.
As part of the trial conducted in 2003–2004 by Alonso and
colleagues to evaluate the efﬁcacy of the RTS,S/AS02A
vaccine in Mozambican children [6], DNA sequences encod-
ing the Th2R and Th3R epitopes of the CSP gene of parasites
from breakthrough cases in both vaccine and control arms of
the trial were obtained during six months of follow-up. These
were analysed to test the hypothesis that protection against
infection or clinical disease following vaccination with RTS,S/
AS02A was not sequence-dependent with regard to the Th2R
and Th3R epitopes of CSP. In addition, we investigated
whether vaccination modiﬁed the number of P. falciparum
genotypes present in infected subjects.
METHODS
Participants
Samples for molecular analysis were collected during the
course of a vaccine trial conducted in the Manhic¸a district,
southern Mozambique, between April 2003 and May 2004.
Details of the study area, population, and study design have
been previously reported [6]. In brief, a Phase IIb, double-
blind, randomised, controlled trial was conducted to deter-
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Editorial Commentary
Background: A recent trial in young children in Mozambique found that
an experimental malaria vaccine, RTS,S/AS02A, reduces the risk of clinical
malaria, delays time to new infection, and reduces episodes of severe
malaria over 18 months. RTS,S/AS02A is based on a particular protein,
the circumsporozoite protein, which is expressed on the surface of the
malaria parasite at a stage in its life cycle prior to the disease-causing
blood-stage infection. Because there are different variants of the
circumsporozoite protein in the parasite population, the researchers
were concerned that the strain-specific protection offered by RTS,S/
AS02A might select for parasites with particular variants of the
circumsporozoite gene. They did a follow-up study to investigate this
concern, looking to see whether vaccinated children who became
infected with malaria had variant forms of the parasite.
What this trial shows: The investigators found that there was no
increase in how different the variants were from the vaccine-type allele
between vaccinated and control individuals. There was a small decrease
in the average number of parasite ‘‘strains’’ in vaccinated children
compared with controls. However, in children within the trial who were
admitted to hospital with clinical malaria, the number of different
‘‘strains’’ of the parasite was no different between vaccinated children
and controls.
Strengths and limitations: The study asks an important molecular
question about whether vaccination with RTS,S/AS02A selects for
different variants, specifically escape mutants of the malaria parasite. If
the researchers had found such selection, this would suggest that the
vaccine’s success could be compromised once widely deployed. A
limitation of this follow-up study is that it is difficult to interpret these
findings because the mode of action of the vaccine is not yet fully
understood. It is also difficult to understand how the results might apply
to non-hospitalised patients with clinical malaria, because the malarial
patients included in this study were exclusively identified through
hospital admissions.
Contribution to the evidence: This study adds molecular information to
the previously reported results on the clinical effectiveness of the RTS,S/
AS02A vaccine. The researchers found no evidence that the RTS,S/AS02A
vaccine selected for different variants of the malaria parasite.
The Editorial Commentary is written by PLoS staff, based on the reports of the
academic editors and peer reviewers.
mine the efﬁcacy of the vaccine against clinical disease and
infection in children aged 1–4 years. These endpoints were
measured in two cohorts based at different sites, Cohorts 1
(Manhic¸a) and Cohort 2 (Ilha Josina). Malaria transmission
intensity is higher in the study area of Cohort 2 than in Cohort
1 [6]. In Cohort 1, 1,605 children were enrolled and the
primary endpoint was time to the ﬁrst clinical episode of
symptomatic P. falciparum malaria over a six-month observa-
tion period starting 14 d after dose 3, corresponding to study
month 2.5, until study month 8.5. In Cohort 2, 417 children
were enrolled and the main endpoint was the efﬁcacy of the
vaccine for prevention of new infections, over the post-
vaccination follow-up period spanning study months 2.5 to
8.5. In Cohort 2, subjects received a single dose of sulfadoxine-
pyrimethamine and a daily dose of amodiaquine for 3 d, 4 wk
prior to the commencement of surveillance and 2 wk prior to
the last dose of vaccine, to clear any parasitaemia.
Samples for parasite genotyping collected from children in
Cohort 1 were obtained from two sources: 1) ﬁlter-paper
bloodspots from a cross-sectional survey conducted at study
month 8.5, and 2) frozen EDTA-blood from patients with
malaria identiﬁed by passive case detection and admissions to
the hospital as in-patients. In Cohort 2, ﬁlter-paper bloodspot
samples were collected from patients with malaria infection
identiﬁed by active detection of infection (see Figure 1). In
both cohorts, only peripheral blood samples from those
children who were fully compliant with the vaccination
protocol were included.
The protocol was approved by the National Mozambican
ethics review committee, the Hospital Clı´nic of Barcelona
ethics review committee, the PATH human subjects protec-
tion committee, and the London School of Hygiene &
Tropical Medicine ethics review committee. Written in-
formed consent was obtained from parents/guardians prior
to study enrollment and blood sample collection.
Blood Sample Collection and DNA Extraction
Filter-paper blood samples were air dried, individually
wrapped in aluminum foil, placed in a box containing
desiccant (silica gel), and stored at 4 8C until use. All samples
were labelled with a unique sample identiﬁcation number.
DNA extraction from one spot (three fragments, approx-
imately 3-mm diameter) of ﬁlter paper and from about 200 ll
of frozen blood samples (hospitalised Cohort 1 participants
only) was performed using the QIAamp DNA blood minikit-
extraction procedure as described by the manufacturer
(Qiagen, Valencia, California, United States). DNA samples
were eluted into 150 ll of buffer AE and stored at20 8C until
use.
Determination of CSP Polymorphic Sequences
The distribution of polymorphic sequence variants encoding
the Th2R and Th3R regions of P. falciparum CSP was
determined using a semi-nested PCR followed by sequencing
of puriﬁed PCR products.
Ampliﬁcation by semi-nested PCR of a 321-bp fragment of
the csp gene was performed using three primers binding to
conserved sequences ﬂanking the Th2R and Th3R regions of
csp. For the ﬁrst round PCR, the primers were: forward
primer (CSo101), 59-aatcaaggtaatggacaagg-39; reverse primer
(CSo102), 59-ctaattaaggaacaagaagg-39. For the second reac-
tion, the primers used were: forward primer (CSo101), reverse
primer (CSo104), 59-ggaacaagaaggataatacc-39. The primers
CSo101 and CSo104 were used to prime sequencing
reactions.
The ﬁrst-round PCR mixture contained 1 ll of DNA in a
total volume of 10 ll containing 200 nM concentrations of
each primer constituted in 13 BioMix Red (Bioline, Boston,
Massachusetts, United States) PCR reaction buffer. The
second PCR mixture contained 1 ll of DNA in a total volume
of 20 ll containing 200 nM of each primer in 13 reaction
buffer. PCR ampliﬁcations were performed in a MJ Research
DYAD 96-well thermocycler with the following cycling
conditions: 95 8C for 4 min, followed by 40 cycles of 94 8C
(1 min), 50 8C (1 min) and 72 8C (1 min) and ﬁnal extension at
72 8C for 4 min. Second-round PCR products were monitored
on a 2.0% agarose gel in 13 TAE buffer to check the quality,
size and yield of the PCR products before proceeding to
product puriﬁcation and sequencing.
After puriﬁcation of PCR products using the QIAquick
multiwell PCR puriﬁcation protocol (Qiagen), sequencing
reactions were performed following the BigDye Terminator
version 3.1 cycle sequencing kit protocol (Applied Biosys-
tems, Foster City, California, United States). In brief, the
PCR-sequencing reaction mixture contained 2 ll puriﬁed
product containing between 10 and 120 ng of PCR product
together with 8.0 ll PCR master mix containing 2 ll of
forward or reverse primer, 0.5 ll BigDye mix, 1.75 ll of
sequencing buffer and puriﬁed water. The PCR ampliﬁcation
was performed in 96-well plates under the following
conditions: 25 cycles of 96 8C for 0.30 min, ramp 1.0 8C/s to
50.0 8C, 50 8C for 0.15 min, ramp 1.0 8C/s to 60.0 8C, 60.0 8C for
4.00 min, ramp 1.0 8C/s to 96.0 8C.
The sequencing products were then precipitated using the
ethanol-sodium acetate precipitation method and placed in
the ABI 3730 capillary sequencing machine for sample
electrophoresis.
Sequence Analysis
The SeqMan software program (DNASTAR, Madison, Wis-
consin, United States) was used to analyse the electrophero-
gram sequences. The sequence of each PCR product was
manually checked by at least two investigators and a
consensus reached or the assay repeated. The forward and
reverse electropherogram sequences were assembled into a
contiguous sequence and the consensus ﬁle examined to
decide whether it represented a single allele or mixed alleles.
Contiguous sequences showing two or more electrophero-
gram peaks in the same position (in which a clearly majority
allele could not be deﬁned) indicated mixed alleles.
The polymorphic variants at both regions of the CSP
sequence (Th2R and Th3R) were scored using the 3D7/NF54
allele as reference. Eighty codons at positions 323–402
(numbered according to the 7G8 sequence [9]) were aligned
for all isolates, and the data entered in an Excel worksheet.
Two separate data ﬁles were created; one for the single and
clear majority alleles and one for all isolates including mixed
alleles. In the ﬁrst data ﬁle, the amino acid in each speciﬁc
position was scored as 1 if it was identical to the amino acid
present at that position in the 3D7/NF54 sequence. Non-
identical amino acids were scored as 0. In the second data ﬁle,
the scoring was as following: 0 for non-vaccine type amino
acid, 1 if only an amino acid identical to the vaccine type
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sequence was present, and 2 if the vaccine type allele was
mixed with other allele(s).
Genotyping of msp-1, msp-2, and glurp for Estimation
of MOI
Nested PCR was used to discriminate alleles of msp-1 block 2
and msp-2 and the R11 repeat region of glurp as previously
described [12].
Following electrophoresis, gels were double-scored inde-
pendently by two investigators, and either consensus was
reached or the assay repeated. The minimum number of
genotypes at each locus was determined for each sample and
the results entered in an Excel worksheet. The overall
genotypic complexity of each isolate was taken as the highest
of the three numbers calculated at each locus. The mean of
this minimum number was then calculated for each group,
and termed the ‘‘multiplicity of infection’’ (MOI). This must
be regarded as a minimum estimate of the true mean MOI
[12].
Blinding
All DNA extractions and laboratory analyses were performed
by individuals blinded to vaccine assignment.
Statistical Methods
An analysis plan was agreed upon prior to decoding the
dataset into treatment groups. The endpoints for assessing
the strain speciﬁcity of the vaccine were: 1) the relative
proportion of the vaccine type allele, for each of the
polymorphic amino acid sites at both T cell epitope regions
(Th2R and Th3R), in the vaccine versus control group. The
Fisher exact test (2-sided) was used to test the differences
between RTS,S/AS02A and control group; and 2) the number
of amino acids different from the vaccine type in each of the
T cell epitope regions (Th2R and Th3R). The differences in
the distribution of the number of amino acids different from
3D7/NF54 between the vaccine and the control groups were
compared using a Mann–Whitney U test (2-sided Wilcoxon
Rank Sum test). Statistical test results were not adjusted for
multiple analyses.
To determine whether the vaccine affected the number of
P. falciparum genotypes per infection, the frequency distribu-
tion of genotypes in vaccinated and control groups were
compared using the Mann–Whitney U test as the primary
outcome. Poisson regression was used to produce estimates of
vaccine effect, adjusted for parasite density, age, and time to
infection. However, the analysis did not produce an outcome
that agreed with the non-parametric analysis, and therefore
we concluded that the Poisson distribution did not ad-
equately describe the data. An adjusted gamma regression was
calculated and is presented as an exploratory (secondary)
analysis, as this was able to ﬁt the data more closely.
RESULTS
Participant Flow
Overall participant ﬂow is summarized in Figure 1. The
number of samples collected and used for sequencing is given
in Table 1, and for estimation of MOI in Table 2.
Numbers Analysed
The RTS,S/AS02A trial conducted in Mozambique enrolled
two cohorts of children, one for estimation of vaccine efﬁcacy
against episodes of clinical malaria (Cohort 1), and the other
for estimation of efﬁcacy against infection (Cohort 2) [6]. In
Cohort 1, 213 parasite-positive individuals were identiﬁed by
the cross-sectional survey for parasite prevalence at study
month 8.5. Of these, 82 were individuals vaccinated with
RTS,S/AS02 and 131 had received control vaccines, repre-
senting 11.9% and 18.9% of participants surveyed in these
two groups, respectively [6]. The csp genes of 208 (98%) of
these were successfully ampliﬁed by PCR and sequenced. The
electropherograms of 109 isolates (52.4%) indicated the
presence of a single csp allele, eight (3.8%) indicated a single
clear majority allele (with small background peaks indicating
minority alleles at one or more of the polymorphic sites), and
91 (43.8%) gave mixed alleles. A total of 95 samples were
analysed from 104 Cohort 1 participants admitted to hospital
with clinical malaria for the ﬁrst or only time: DNA from 90
of these (94.7%) was successfully ampliﬁed and sequenced.
Forty-one (45.5%) of the PCR products gave electrophero-
grams consistent with a single allele, 11 (12.3%) a single clear
majority allele in the presence of small background peaks,
and 38 (42.2%) were mixed alleles.
In Cohort 2, there were 323 children with ﬁrst episodes of
parasitaemia detected, but 82 of these children did not have a
ﬁlter paper sample collected. The majority of these 82
samples corresponded to children who were febrile at the
home visit and thus sent directly to the outpatient clinic
where blood smear and microcapillary samples were taken,
but ﬁlter paper was not. Thus DNA samples for genotyping
analysis were available for 241 children with parasitaemia,
and 223 (92.5%) of these samples were successfully ampliﬁed
by PCR and the products sequenced. Of these, 157 (70.4%)
contained a single allele, eight (3.6%) a single clear majority
allele with small background peaks, and 58 (26%) gave mixed
alleles. The observation of fewer mixed infections in Cohort 2
than in Cohort 1 may be at least partially explained by
differences in both intervention and surveillance phases of
the study. Children in Cohort 2 received anti-malarial
treatment two weeks before the third dose of vaccine to
clear parasitaemia prior to the start of the efﬁcacy follow-up
period, and underwent biweekly active detection and treat-
ment of infection. Following up in Cohort 1 was by passive
detection of malaria cases.
Outcomes and Estimation
In each cohort we determined 1) the proportion of isolates
with the CSP vaccine type (3D7) at each polymorphic amino
acid position in the Th2R and Th3R epitopes in the vaccine
and control groups; and 2) the number of amino acids
different from vaccine type (3D7) within the Th2R and Th3R
regions in the vaccine versus control group. There were eight
and six amino acid positions in the Th2R and Th3R regions of
the CSP sequence, respectively, which displayed polymor-
phism in our population and were therefore informative.
Primary comparative analyses were performed using a
conservative dataset comprising both mono-allelic isolates,
and those isolates with a single clear majority allele against a
background of one or more minor alleles. Mixed-genotype
isolates were included in secondary comparative analyses.
Comparisons between groups were performed using Fish-
er’s exact tests and by evaluating the 95% CI of the
differences between groups. Post hoc, the study had the
power to detect any between-group differences in the
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proportion of non-vaccine amino acid residues in the Th2R
and Th3R epitope regions of at least 25% (cross-sectional
survey in Cohort 1, conservative dataset) and of at least 20%
for the other datasets.
The proportion of isolates that contained non-vaccine
residues in the CSP Th2R and Th3R epitopes are shown in
Figure 2. Among isolates collected at study month 8.5 from
children in Cohort 1, primary analysis revealed no signiﬁcant
differences between vaccine and control groups at any amino
acid positions in the Th2R region, nor at any position in the
Th3R region. Similarly, no signiﬁcant differences were found
between treatment groups in the Cohort 1 participants
admitted to hospital at any position in either epitope region.
Among infections detected in Cohort 2, the vaccine-type
residue 374-Asp in the Th3R epitope was replaced by Asn in
4% of the vaccine group infections, compared with 13% in
the control group (difference in proportions 9%, 95% CI
0.8%–17.2%; p ¼ 0.050), but there were no other signiﬁcant
differences between treatment groups in Cohort 2 at any
position in either epitope region.
Ancillary Analyses
In secondary analysis of Cohort 1 data at study month 8.5,
including counts from mixed-allele infections, the vaccine-
type Glu at residue 333 (Th2R) was replaced by Gln or Lys in
76% of vaccine group samples, compared with 64% of
control samples (difference in proportions 12.5%, 95% CI
25% to 0.1%; p¼ 0.066), and the vaccine type Lys present at
Figure 1. Participant Flow and Samples Analysed
The diagram begins with the per-protocol efficacy cohort described in Figures 2 and 3 of [6].
DOI: 10.1371/journal.pctr.0010005.g001
.......................................................................................................................................................................................
Table 1. Overview of Data Used for Sequencing Analysis
Sample Numbers Cohort 1 (Study Month 8.5) Cohort 1 (Admitted to Hospital
by Passive Case Detection)
Cohort 2
RTS,S/AS02A Control Total RTS,S/AS02A Control Total RTS,S/AS02A Control Total
Number of cases 82 131 213 42 62 104 157 166 323
Number of cases for
which analysis is available
80 128 208 36 54 90 106 117 223
Reasons for non-availability Filter paper sample not collected: n ¼ 1;
PCR result negative: n ¼ 4
Filter paper sample not collected: n ¼ 9;
PCR result negative: n ¼ 5
Filter paper sample not collected: n ¼ 82;
PCR result negative: n ¼ 18
DOI: 10.1371/journal.pctr.0010005.t001..
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residue 337 in the Th2R region was replaced by Thr, Arg, or
IIe in 52% of vaccine group samples compared with 38% of
control samples (difference in proportions 14.7%, 95% CI
28.5% to 0.9%; p ¼ 0.044). In Cohort 2, the vaccine-type
residue 374-Asp in the Th3R epitope was replaced by Asn in
3% of the vaccine group infections when mixed alleles were
included, compared with 9% in the control group (difference
in proportions 6.6%, 95% CI 0.4%–12.7%; p ¼ 0.054).
Signiﬁcant differences in substitution patterns between the
control and vaccine groups were not seen at any other amino
acid position in secondary analyses.
We estimated the number of amino acids that differed from
the vaccine type for each isolate. No signiﬁcant differences
were found between vaccine and control groups at either the
Th2R or Th3R epitope regions in either cohort (Figure 3).
Only three children (1.6%) from the control group and three
children (2.0%) from the vaccine group harboured parasites
with Th2R epitopes identical to those of the vaccine strain.
Th3R epitope sequences identical to 3D7/NF54 were found in
six children (3.2%) and ﬁve children (3.4%) in the control and
vaccine groups, respectively. This contrasts to prevalences of
10% and 15%, respectively, among adult men in Gambia [11].
Multiplicity of Infection
Parasite DNA from 208 samples from Cohort 1 (surveyed in
study month 8.5), 95 from Cohort 1 children admitted to
.......................................................................................................................................................................................
Table 2. Overview of Data Used for MOI Analysis
Sample Numbers Cohort 1 (Study Month 8.5) Cohort 1 (Admitted to Hospital
by Passive Case Detection)
Cohort 2
RTS,S/AS02A Control Total RTS,S/AS02A Control Total RTS,S/AS02A Control Total
Number of cases 82 131 213 42 62 104 157 166 323
Number of cases for
which analysis is availablea
79 129 208 38 57 95 105 119 224
Reasons for non-availability Filter paper sample not collected:
n ¼ 1; PCR result negative: n ¼ 4
Filter paper sample not collected: n ¼ 9;
PCR result negative: n ¼ 0
Filter paper sample not collected: n ¼ 82;
PCR result negative n ¼ 17
aIndicates the number of cases for which analysis at all three loci is available for the overall MOI (i.e., msp-1þmsp-2þ glurp).
DOI: 10.1371/journal.pctr.0010005.t002..
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Figure 2. Percentage of the CSP Non-Vaccine Type Alleles for All Polymorphic Amino Acid Sites in the Th2R and Th3R Region in the RTS,S/AS02A
Vaccine and Control Groups
Denominators were, for Cohort 1, month 8.5 survey: n¼ 49, 68, in vaccine and control groups, respectively; for Cohort 1 hospital-admitted children: n¼
19, 33; for Cohort 2: n¼ 79, 86.
DOI: 10.1371/journal.pctr.0010005.g002
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hospital, and 224 samples from Cohort 2 children, was typed
successfully for msp-1, msp-2, and glurp genes and used for the
analysis of MOI (Table 2).
For Cohort 1 (study month 8.5) and Cohort 2, the overall
minimum MOI (combining the data from the three loci) was
signiﬁcantly lower among infections in the vaccine group
than among those in the control group (p ¼ 0.035, p ¼ 0.006,
respectively, for the two cohorts, Wilcoxon rank sum test)
(Figure 4). The mean MOI for Cohort 1 was 1.94 (sd 0.94) in
the RTS,S/AS02A group and 2.24 (sd 1.01) among controls
(proportional difference from gamma regression adjusted for
parasite density 0.9; 95% C.I. 0.79–1.02; p¼ 0.098). Mean MOI
for Cohort 2 was 1.83 (sd 0.89) and 2.16 (sd 0.97), respectively,
for vaccine and control groups (proportional difference from
Figure 3. Proportion of Parasites with Given Numbers (x-axis) of Amino Acids Different from the Vaccine Type (3D7) in the Th2R and Th3R Region of
CSP, in the Vaccine versus Control Groups
Denominators were, for Cohort 1, month 8.5 survey: n¼49, 68, in vaccine and control groups, respectively; for Cohort 1 hospital-admitted children: n¼
19, 33; for Cohort 2: n¼ 79, 86.
DOI: 10.1371/journal.pctr.0010005.g003
Figure 4. MOI in Emergent Infections for Both Vaccine and Control Groups
Denominators were for Cohort 1, month 8.5 survey: n¼ 79, 129, in vaccine and control groups, respectively; for Cohort 1, hospital-admitted: n¼ 38, 57;
for Cohort 2: n¼ 105, 119.
DOI: 10.1371/journal.pctr.0010005.g004
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gamma regression, adjusted for parasite density and time to
infection 0.84; 95% CI 0.74–0.96; p¼ 0.007). Among Cohort 1
participants who were admitted to hospital, there was no
signiﬁcant difference between the vaccine (mean MOI 2.84, sd
1.08) and control groups (mean MOI 2.67, sd 0.87) in the
genotypic complexity of infection analysis as indicated by the
Wilcoxon test (p¼ 0.478) and the gamma regression adjusted
for parasite density and disease severity (proportional
difference 1.12; 95% CI 0.96–1.30; p ¼ 0.154).
DISCUSSION
Preventive measures against malaria disease and mortality are
needed urgently as we enter the 21st century with a malaria
burden among African children unchanged since the begin-
ning of the previous century. The demonstration by Alonso et
al. [6] that vaccination of children 1 to 4 years of age in
Mozambique with GSK Biologicals candidate malaria vaccine
RTS,S/AS02A protects against both infection and a range of
clinical manifestations of malaria including severe disease,
and that this protection is sustained over at least 18 months
[7], is timely proof that development of an effective vaccine
against malaria is feasible. The target antigen in RTS,S/
AS02A, CSP of P. falciparum, includes regions that are highly
polymorphic and may exist as dozens of variants within any
given parasite population [8,9,11]. If the efﬁcacy of RTS,S/
AS02A is sequence-dependent, then protection may vary
depending on the divergence of the CSP sequence in the
predominant circulating strains. Theoretically, if a vaccine
were widely deployed, sequence-dependent protection could
select for genotypes at a parasite population level. We report
here that among emergent P. falciparum infections in 222
vaccinated children as compared to 299 control individuals
participating in the Mozambique trial of RTS,S/AS02A in
2003–2004 there was no evidence for selection of genotypes
that differed in sequence from the vaccine type.
Interpretation
The absence of measurable sequence-dependent selection in
the Th2R and Th3R regions does not imply that a
contribution of vaccine-induced cellular immune responses
to the observed efﬁcacy of RTS,S/AS02A can be ruled out.
Indeed, there is ample evidence that humans vaccinated with
RTS,S/AS02A generate immune responses to both epitopes
[13,14], although a formal link between these responses and
protection has yet to be made. CD4þ T cell responses to an
invariant CSP epitope present in RTS,S have been associated
with natural protection against infection [15], and recent
genetic analysis of csp sequences encoding theTh2R and Th3R
epitopes in 238 isolates from Thailand does not support the
notion that diversity in these epitopes is generated in
response to selection by sequence-speciﬁc human immunity
in that population [16]. Furthermore, vaccination with RTS,S/
AS02A may elicit T cell responses against the polymorphic
region of CSP that recognises heterologous T cell epitopes, as
both cross-clade recognition by HIV-speciﬁc T cells [17,18]
and cross-reactivity of HPV-11 speciﬁc CD4þ T cells with
other skin and genital HPV types [19] have been reported.
Ongoing and future trials of RTS,S-based vaccines may shed
light on the role of cell-mediated immune responses to
conserved and polymorphic epitopes in the observed
protection induced by the vaccine.
Generalisability
Our analysis of sequence-dependent vaccine efﬁcacy used
direct-sequencing of DNA ampliﬁed directly from blood
samples. All processes were performed in 96-well format from
DNA extraction through to data collection. This innovative
approach provides advantages over the dot-blot hybridisation
method of Alloueche et al. [9,11] in being faster, easier to
automate, and more robust, as the earlier method requires
skill in interpretation of complex arrays of dot-blot data, and
multiple reads by independent workers to eliminate observer
error. The only limitation we encountered with direct
sequencing was that a proportion of isolates were too
complex at the nucleotide positions of interest in the
Th2R- and Th3R-encoding regions of csp, due to the presence
of multiple genotypes with different csp alleles, to unequiv-
ocally assign a full sequence. Thus, 43.8% of isolates from
Cohort 1 and 26% from Cohort 2 were of mixed csp genotype
with no clear majority allele, and did not contribute to our
primary sequence analysis. This may potentially bias our
ﬁndings if sequence-dependent selection occurs more com-
monly among these complex infections. This limitation also
applies to dot-blotting methods, but could be addressed in
future studies by cloning out and sequencing individual csp
alleles from such mixed infections, adding substantially to the
analysis effort.
An important parasitological parameter used in many
clinical and epidemiological studies of malaria is the mean
number of distinct parasite genotypes per infected individ-
ual, or MOI [12,20]. Studies of possible associations between
MOI and risk of clinical malaria in Ghana, Mozambique,
Tanzania, and PNG have been inconsistent [21–24], and as the
relationship between MOI and malaria morbidity is possibly
age-dependent [22], this is likely to vary considerably under
different transmission conditions. Therefore, we must be
cautious when interpreting our data about MOI. Indeed,
evidence of a reduction in MOI was found in children
vaccinated with the synthetic polypeptide vaccine SPf66 in
Tanzania [25] and in Gambia [26], although the vaccine
reduced risk of malaria in Tanzania [27] but not in Gambia
[28]. Conversely, an increase in overall MOI was observed
among Gambian men vaccinated with RTS,S/AS02A [11] who
experienced a delayed time to ﬁrst infection [4]. Among 527
emergent infections in the Mozambique trial, there was a
reduction of MOI in RTS,S/AS02A-vaccinated children
compared with controls both in Cohort 1 (at study month
8.5; p ¼ 0.035) and in Cohort 2 (p ¼ 0.006). No difference in
MOI between RTS,S/AS02A-vaccinated children and control
individuals was observed among Cohort 1 participants
admitted to hospital with clinical malaria. The mechanism
by which an efﬁcacious vaccine might reduce MOI among
emergent infections remains unclear, but in our analysis the
reduction effect was shown to be independent of both
parasite density and time to infection. A pre-erythrocytic
vaccine such as RTS,S/AS02A may work in part by preventing
or reducing emergence of parasites from the liver stage [3,5].
Our ﬁnding that there was no reduction in MOI in RTS,S/
AS02-vaccinated children admitted to hospital with malaria
may represent the emergence of new clones and is consistent
with the hypothesis that new parasite types are more likely to
cause illness than are those types already established in the
host.
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Overall Evidence
We have found no evidence that the observed efﬁcacy against
malaria infection and morbidity of the RTS,S/AS02A vaccine
among Mozambican children is sequence-dependent, and we
have shown that fewer distinct parasite genotypes circulate in
vaccinated hosts compared with controls. There has been no
systematic review of genotypic multiplicity in the context of
vaccination with RTS,S/AS02A. However, an analysis of a
previous RTS,S vaccine trial conducted in Gambian adults [4]
also revealed no differences in the prevalence of vaccine-type
allele sequences among breakthrough infections between
vaccine or control groups [11]. Moreover, although the
vaccine reduced the incidence of infection in that trial, it
did not reduce the MOI compared with controls. Although a
genetic analysis of CSP T cell polymorphisms in individuals
exposed to falciparum malaria along the Thai–Burmese
border [16] indicated that naturally acquired immune
pressure in the human host is unlikely to play any signiﬁcant
role in selecting and maintaining the extensive polymor-
phisms that occur naturally in the CSP Th2R and Th3R
regions, such responses are typically weak and short-lived.
This does not appear to be the case in the context of
vaccination with RTS,S/AS02A [15,29], and the observation
that vaccine-induced selection of escape mutants does not
occur bodes well for candidate vaccines based on the CSP
antigen.
These data were accrued in the context of a large Phase IIb
trial. Nevertheless, should RTS,S/AS02A or similar pre-
erythrocytic malaria vaccines be deployed on a large scale
in the future, surveillance for evidence of sequence-depend-
ent selection of breakthrough parasite genotypes would be a
wise precaution. We have demonstrated that high-throughput
direct sequencing of large numbers of ﬁeld samples from
parasite-positive individuals would be a feasible and robust
approach to this end.
SUPPORTING INFORMATION
CONSORT Checklist
The trial protocol and CONSORT checklist list for the main trial
have been previously published [6,7].
Found at DOI: 10.1371/journal.pctr.0010005.sd001 (49 KB DOC).
Trial Protocol
Found at DOI: 10.1371/journal.pctr.0010005.sd002 (71 KB DOC).
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